Clinical Pharmacology Archives

Blog

Reflections on the New FDA Clinical Pharmacology Guidance for Antibody-Drug Conjugates

In recent years, oncology drug developers have invested in antibody-drug conjugates (ADCs). These targeted therapies…

CertaraMay 10, 2024

Press Coverage

Modeling and simulation in pediatric drug development

Published: December 21, 2023 This is the article written in German, published on pharmind. Children's…

CertaraDecember 21, 2023

Conference

American College of Toxicology 2025 Annual Meeting

– – Booth

CertaraMay 24, 2023

Conference

ACoP 2025

CertaraMay 24, 2023

Case Study

Translational Pharmacology Consulting Supports Combination Therapy for Treating Pulmonary Mycobacterium Avium Complex Disease

RedHill Biopharma Ltd., a specialty biopharmaceutical company, developed RHB-204, a treatment for MAC, and needed…

CertaraMay 9, 2023

On-Demand Webinar

Therapeutic Proteins’ Drug-Drug Interactions: Updates & Challenges

Therapeutic proteins (TP) - and more specifically monoclonal antibodies - are part of the therapeutic…

CertaraDecember 5, 2022

Blog

Why you should select your drug formulation before starting clinical studies

Drug developers often rush through the discovery process to get into human testing. Most are…

CertaraOctober 28, 2022

Blog

3 Takeaways from the FDA Oligo Guidance You Need to Know

In June 2022, the FDA published their first oligonucleotide clinical pharmacology specific guidance . This…

CertaraSeptember 23, 2022

Conference

ACCP Annual Meeting

– – Booth

CertaraJuly 15, 2022

White Paper

The Essential Components of Your Drug’s Biomarker Strategy

CertaraJanuary 14, 2022

Clinical Pharmacology

Reflections on the New FDA Clinical Pharmacology Guidance for Antibody-Drug Conjugates

Modeling and simulation in pediatric drug development

American College of Toxicology 2025 Annual Meeting

ACoP 2025

Translational Pharmacology Consulting Supports Combination Therapy for Treating Pulmonary Mycobacterium Avium Complex Disease

Therapeutic Proteins’ Drug-Drug Interactions: Updates & Challenges

Why you should select your drug formulation before starting clinical studies

3 Takeaways from the FDA Oligo Guidance You Need to Know

ACCP Annual Meeting

The Essential Components of Your Drug’s Biomarker Strategy

Newsletter sign up

Quick links

Solutions

Contact